The OSUCCC Leukemia Tissue Bank Shared Resource (LTBSR) was established in 1997 and since its inception has obtained over 10,000 samples procured from 4,000 consented patients at OSU. The LTBSR successfully facilitates translation of basic research in leukemia to the clinical setting by making available an extensive repository of tissue samples, with accompanying complete pathologic and clinical data, procured from leukemia patients. The infrastructure of the OSUCCC LTBSR is supported by outstanding institutional support and is directed by Dr. Guido Marcucci, a physician-scientist and an established senior investigator in translational research in leukemia. He oversees a highly-trained staff with extensive experience in leukemia research that provides a full array of unique services to support high quality leukemia research. The LTBSR consists of a large and unique leukemia tissue repository, including both leukemic tissue and normal tissue germ line DNA, accompanied in all cases with complete pathologic, cytogenetic and clinical data for ready correlation of clinical and biological results. In addition, all the essentials of effective leukemia tissue bank management are very well-developed, including the activities of tissue collection, best practices, quality control of specimens, tissue storage, procurement of initial and follow-up samples and their pathology and clinical information, data entry and database management, and patient consent and confidentiality. The LTBSR leverages key partnerships within .the OSUCCC and efficient coordination with other key OSUCCC Shared Resources, to provide fundamental support of a key research mission of the OSUCCC: to produce high-quality basic and clinical research in hematological malignancy. While separated with regard to the mechanisms of collecting samples and allocation of samples to investigators, the LTBSR and the OSUCCC Biorepository and Biospecimen Shared Resource for solid tumors are governed by the same operational procedures with regard to commitment to the OSUCCC research mission and patients'confidentiality. The procedures for prioritizing and distributing tissue to a large base of investigators within the OSUCCC are effectively in place. The success in managing this large leukemia tissue resource is well-supported by the broad usage of this resource by >92% OSUCCC members and by high-impact publications (e.g.. Cell, Cancer Cell, Journal Clinical Oncology, Blood) by OSUCCC investigators in which the LTBSR has played a significant role.

Public Health Relevance

The OSUCCC Leukemia Tissue Bank Shared Resource (LTBSR) leverages outstanding institutional support to facilitate the translation of basic research in leukemia to the clinical setting by making available an extensive repository of blood and bone marrow samples, with accompanying complete pathologic and clinical data, procured from leukemia patients. Services provided through the LTBSR promote best practices and provide quality control of specimens from procurement to their use in high quality cancer research discovery, while maintaining patient consent and confidentiality.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-37
Application #
8567300
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
37
Fiscal Year
2013
Total Cost
$43,416
Indirect Cost
$14,947
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Nguyen, Phuong; Wuthrick, Evan; Chablani, Priyanka et al. (2018) Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience. Am J Clin Oncol 41:140-146
Elchuri, Sailaja V; Rajasekaran, Swetha; Miles, Wayne O (2018) RNA-Sequencing of Primary Retinoblastoma Tumors Provides New Insights and Challenges Into Tumor Development. Front Genet 9:170
Reiff, Sean D; Muhowski, Elizabeth M; Guinn, Daphne et al. (2018) Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. Blood 132:1039-1049
Nabar, Gauri M; Mahajan, Kalpesh D; Calhoun, Mark A et al. (2018) Micelle-templated, poly(lactic-co-glycolic acid) nanoparticles for hydrophobic drug delivery. Int J Nanomedicine 13:351-366
Tang, Xiaowen; Yang, Lin; Li, Zheng et al. (2018) First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res 8:1083-1089
Lai, Xiulan; Stiff, Andrew; Duggan, Megan et al. (2018) Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. Proc Natl Acad Sci U S A 115:5534-5539
Rolfo, Christian; Mack, Philip C; Scagliotti, Giorgio V et al. (2018) Liquid Biopsy for Advanced Non-Small Cell LungĀ Cancer (NSCLC): A Statement Paper from theĀ IASLC. J Thorac Oncol 13:1248-1268
Ren, Yulin; Gallucci, Judith C; Li, Xinxin et al. (2018) Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens. J Nat Prod 81:554-561
McDonald, J Tyson; Kritharis, Athena; Beheshti, Afshin et al. (2018) Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. Oncotarget 9:22693-22702
Reiter, Paul L; Shoben, Abigail B; McDonough, Deborah et al. (2018) Results of a Pilot Study of a Mail-Based HPV Self-Testing Program for Underscreened Women from Appalachian Ohio. Sex Transm Dis :

Showing the most recent 10 out of 2602 publications